Gene therapy has always held enormous promise to correct genetic diseases, but turning that potential into treatments has been challenging. In the latest case, the scientists developed a CRISPR ...

We're living in a moment where science fiction is becoming medical reality. Imagine a world where doctors can simply rewrite the genetic code that condemns someone to a lifetime of suffering.No more ...

When you buy through links on our articles, Future and its syndication partners may earn a commission. In a world first, a baby in the U.S. received a personalized, CRISPR-based gene therapy that ...

A baby born with a rare and dangerous genetic disease is growing and thriving after getting an experimental gene editing treatment made just for him. Researchers described the case in a new study, ...

Vertex recently said the product may deliver more than $100 million in revenue in the 2025 full year. But it's important to ...

The company does possess a lot of potential, with its approved gene-editing treatment Casgevy. Unfortunately, sales from that haven't exactly been soaring, and thus its financial performance has ...

BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced today that the U.S. Food and Drug Administration (FDA) ...

In a new study, scientists at the Max Planck Institute for Evolutionary Anthropology in Leipzig analyzed the impact of more than 2,000 clinically approved drugs on DNA repair and CRISPR genome editing ...

A new study from the Max Planck Institute for Evolutionary Anthropology examined how > 2,000 clinically approved drugs affect DNA repair and CRISPR genome editing.